Reply To: Avacta

Nick Hargrave

Continued positive news from Avacta with their detailed Phase 1a data release, confirming that the PreCision platform is working as intended while positive signs of efficacy have been seen even during the safety phase of the trial. With this release of data we hope to see some commercial activity in the coming months related to the PreCision platform, validating its value and providing non-dilutive funding for continued development